The U.S. FDA has allowed Fate Therapeutics’ Investigational New Drug (IND) Application for FT500, positioning the company to launch the first clinical trial investigation of an iPSC-derived cell product within the United States.
FT500 is a universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line. Fate Therapeutics broke this exciting news in an announcement released November 30, 2018. [Read more…]